This Is MS Multiple Sclerosis Knowledge & Support Community

Phase 2b in progress : PRESS RELEASE GeNeuro and Servier sign partnership to develop first medicine addressing a causal factor of Multiple Sclerosis • GeNeuro responsible for development of GNbAC1 till completion of Phase IIb in Multiple Sclerosis, receiving $47M from Servier, after which Servier ca...

For information, Geneuro Company is going to present the results there :

http://www.msboston2014.org/

Here are the posters :

http://www.abstractstosubmit.com/msbost ... ?d=243&t=f&
http://www.abstractstosubmit.com/msbost ... ?d=193&t=f&

Hello, Here is the last communication from Geneuro : September 5, 2014 Novel MS Therapy from GeNeuro Performed Well in Phase 2a Clinical Trial A novel therapeutic from GeNeuro to treatmultiple sclerosis showed promising results in a one-year, open-label extension phase 2a clinical trial. GeNeuro tes...

Hello everybody. As I explained, Geneuro in Swiss developped the humanized monoclonal antibody, and drove Phase 1 and phase 2a regarding clinical test (10 persons in phase 2a). Geneuro already received some proposals regard in partnership and contacts with big pharmas, especially in US, to continue ...

Hi Gogo, Sorry I didn't see your post. I am in progressive stage. Regarding this first clinical trial with only 10 people, all were in progressive stage. As I said, some of them felt some improvements even if it was not the target of this trial, done to test the safety. It is too early to get some c...

Some news, phase 2b in 2014 in some places in Europe. Please read the information given 2 days ago. I stopped myself this study, due to the very low dose (2mg/kg) I received with no effect and because swiitzerland is far away from my home. GeNeuro Successfully Completes Phase 2a Clinical Study with ...

Hello, Regarding the current clinical test, the complete results will be given in June. During the AAN congress, only preliminary information has been given regarding the good tolerability of the product. In June, the complete results will include pharmacokinetic data. The decision of extension of t...

Hello, As I indicated, all patients (10) now received one single dose, 2mg or 6 mg/kg. No side effects for anyone. The target of this phase 2a was to check the security aspect. Now, the six-month repeated-dose extension started. Again, no side effects for anyone. I personnally received 3 times 2mg/k...

Good question, but I don't have any data regarding this point.

Schizophrenia is still in preclinical phase.

American Academy of Neurology - San Diego - 16th to 23rd March

The first results of the Phase IIa study in MS patients with GeNeuro GNbAC1 monoclonal antibody will be presented at the 65th AAN annual meeting.

www.aan.com

For information, I received today the confirmation that the six-month repeated-dose extension has just been agreed. It means that those who have been involved in IIa phase, will start this extension in January 2013, and will receive the first monthly dose. Please note you have the possibility to tra...

Hello everybody :smile: I am involved in the following study, described hereafter. Mister Hervé Perron, who found the retrovirus, gave more details here : http://www.forseps.org/t1921-reponses-sur-le-retrovirus (in French), and you can follow my experience regarding this test here : http://www.forse...

Hi girl69, I have been in Bulgaria in February for this specific infusion of autologous stem cells. I am French, EDSS 4, SPMS. I am not sure to have many details to give you, they took the autologous stem cells from bone marrow the morning, and after filtration they injected again the stem cells the...

Hello Why

Yes, I have been in Poland the 25th of May.
I had balooning both sides in jugulars.

I feel improvement in my ability to walk a longer time, but at this moment there is a small improvement, and it is difficult to appreciate if it is really there..

Have a good day,

Fred

Hello Everybody

We have got now on Forsep's home page a link to Thisisms, because this website contonues to be for us an important source of information !!

Have a very good day,

Fred